摘要
沙利度胺早期作为一种非巴比妥类镇静剂用于早孕反应的治疗,但由于严重的致畸作用而被禁用。随后的研究发现,沙利度胺具有抑制肿瘤坏死因子-α(TNF-α)作用,1998年美国FDA批准其用于麻风病结节性红斑的治疗。近年来研究发现,沙利度胺具有抗血管生成及调节免疫等作用。目前,沙利度胺已经成为复发和难治性骨髓瘤标准治疗的一部分,和其他药物联合应用对其他实体肿瘤如神经胶质细胞瘤、前列腺癌、肾癌、恶性黑色素瘤和肺癌等的治疗显示一定效果,但其作用机制尚不完全明了。
Thalidomide, initially introduced as a non-barbital sedative on nausea of morning sickness in pregnant women, was prohibited to use because of its severe teratogenicity. It was permitted by FDA to be used in the treatment of erythema nodosum leprosum due to its inhibition on TNF-α in 1998. Recent studies show that thalidomide has a potential activity of anti-inflammatory and an ti-angiogenesis. Thalidomide has already become a part of standard therapy in the treatment of patients with relapsed and refractory multiple myeloma. The combination of thalidomide and other effective drug in solid tumor has demonstrated a useful activity, especially in neurogliocytoma, prostatic carcinoma, renal carcinoma, malignant melanoma and lung cancer. However, its mechanism is still incompletely clear.
出处
《中华肿瘤防治杂志》
CAS
2007年第16期1265-1268,共4页
Chinese Journal of Cancer Prevention and Treatment
